The estimated Net Worth of John E. (Jack) Jr. Bailey is at least $4.84 Million dollars as of 5 July 2024. Mr. Bailey owns over 7,662 units of G1 Therapeutics Inc stock worth over $3,919,176 and over the last 5 years he sold GTHX stock worth over $922,522. In addition, he makes $0 as Independent Director at G1 Therapeutics Inc.
Sign up
Mr. Bailey GTHX stock SEC Form 4 insiders trading
John has made over 8 trades of the G1 Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 7,662 units of GTHX stock worth $19,232 on 5 July 2024.
The largest trade he's ever made was selling 37,626 units of G1 Therapeutics Inc stock on 3 January 2023 worth over $218,607. On average, John trades about 13,235 units every 103 days since 2020. As of 5 July 2024 he still owns at least 549,674 units of G1 Therapeutics Inc stock.
You can see the complete history of Mr. Bailey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Bailey biography
John E. Bailey Jr. has been appointed as President, Chief Executive Officer, Director of the Company effective 1/1/2021. He has served as a member of the Board since March 2020. Mr. Bailey has nearly thirty years of commercial pharmaceutical experience. Mr. Bailey led the United States and Puerto Rico therapeutic divisions of respiratory, vaccines, immunology/rare diseases and oncology at GlaxoSmithKline plc from February 2015 to January 2020. Earlier in his career, Mr. Bailey served in various leadership capacities at Eli Lilly and Company, including as Senior Vice President of the Account-Based Markets Division. Mr. Bailey currently serves on the board of directors of Emergo Therapeutics, Inc., a privately held biopharmaceutical company, the Advisory Council for the T.H. Chan School of Public Health at Harvard University and the Corporate Advisory Board for the Center for the Business of Health, an academic center housed in the UNC Kenan-Flagler Business School. Mr. Bailey is also a past member of the board of directors of PhRMA, the pharmaceutical industry trade association, and the North Carolina Biotechnology Center, a life science economic development organization. Mr. Bailey earned a B.S. in Biology from Hobart College and an M.B.A. from the University of North Carolina, Chapel Hill.
How old is John Bailey?
John Bailey is 56, he's been the Independent Director of G1 Therapeutics Inc since 2020. There are 13 older and 12 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.
What's John Bailey's mailing address?
John's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.
Insiders trading at G1 Therapeutics Inc
Over the last 7 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
What does G1 Therapeutics Inc do?
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
What does G1 Therapeutics Inc's logo look like?
Complete history of Mr. Bailey stock trades at G1 Therapeutics Inc
G1 Therapeutics Inc executives and stock owners
G1 Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Avagliano,
Chief Business Officer -
James Hanson,
General Counsel, Secretary -
Mark Velleca,
President, Chief Executive Officer, Director -
Terry Murdock,
Chief Operating Officer -
Garry Nicholson,
Independent Chairman of the Board -
Jennifer Moses,
Chief Financial Officer -
Rajesh Malik,
Chief Medical Officer, Senior Vice President - Research and Development -
Dr. Mark A. Velleca M.D., Ph.D.,
Sr. Advisor & Director -
Mark Avagliano,
Chief Bus. Officer -
Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
Chief Medical Officer and Sr. VP of R&D -
Dr. Rajesh K. Malik,
Chief Medical Officer and Sr. VP of R&D -
Andrew Perry,
Chief Commercial Officer -
Jennifer K. Moses CPA,
Chief Financial Officer -
Jennifer K. Moses,
Chief Financial Officer -
Seth Rudnick,
Independent Director -
Glenn Muir,
Independent Director -
Cynthia Schwalm,
Independent Director -
Fredric Eshelman,
Independent Director -
Willie Deese,
Independent Director -
Andrew Witty,
Independent Director -
John Bailey,
Independent Director -
Soma Gupta,
Chief Commercial Officer -
Jay Strum,
Chief Scientific Officer -
Terry L. Murdock,
Chief Operating Officer -
Blake Jensen,
VP of Quality & Compliance -
William C. Roberts,
VP of Investor Relations & Corp. Communications -
Dr. Jay C. Strum,
Chief Scientific Officer -
Alexander D. Smith M.S.,
VP of Technical Operations -
John E. Bailey Jr.,
CEO, Pres & Director -
Clay Hatteras Venture Advis...,
-
Capital Management, L.P.Ra ...,
-
Christy L Shaffer,
Director -
Ventures, Inc. Med Immune,
10% owner -
Ventures, Llc Eshelman,
10% owner -
Clay Hatteras Venture Advis...,
-
Barclay A Phillips,
SVP & Chief Financial Officer -
Monica R. Thomas,
Chief Legal & People Officer -
Jacks Lee,
-
John Demaree,
Chief Commercial Officer -
Alicia Secor,
-
Cynthia Louise Flowers,
-
Andrew Perry,
Chief Commercial Officer -
Norman Sharpless,
-
John W. V Umstead,
Chief Financial Officer